Canterbury Park Holding (CPHC) Is At $14.35 Formed Wedge; Sorrento Therapeutics (SRNE) Shorts Decreased By 3.53%

Canterbury Park Holding Corporation (CPHC) formed wedge down with $13.35 target or 7.00% below today’s $14.35 share price. Canterbury Park Holding Corporation (CPHC) has $63.29 million valuation. The stock decreased 2.38% or $0.35 during the last trading session, reaching $14.35. About 2,276 shares traded. Canterbury Park Holding Corporation (NASDAQ:CPHC) has risen 9.54% since February 28, 2017 and is uptrending. It has underperformed by 7.16% the S&P500.

Sorrento Therapeutics Inc (NASDAQ:SRNE) had a decrease of 3.53% in short interest. SRNE’s SI was 3.11 million shares in February as released by FINRA. Its down 3.53% from 3.23 million shares previously. With 3.48 million avg volume, 1 days are for Sorrento Therapeutics Inc (NASDAQ:SRNE)’s short sellers to cover SRNE’s short positions. The SI to Sorrento Therapeutics Inc’s float is 7.21%. The stock decreased 4.52% or $0.4 during the last trading session, reaching $8.45. About 3.11M shares traded or 27.52% up from the average. Sorrento Therapeutics, Inc. (NASDAQ:SRNE) has declined 73.31% since February 28, 2017 and is downtrending. It has underperformed by 90.01% the S&P500.

Since January 23, 2018, it had 0 insider purchases, and 4 insider sales for $12.65 million activity. ABG Management Ltd sold $2.37 million worth of stock or 310,000 shares. 684,288 shares were sold by Asia Pacific MedTech (BVI) Ltd, worth $5.18 million.

Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The company has market cap of $698.76 million. It develops therapeutic products for the treatment of auto-immune, inflammatory, neurodegenerative, and infectious diseases. It currently has negative earnings. The firm offers resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin for the treatment of intractable pain at end-stage disease.